Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06520878Phase 2Recruiting

Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment

Role: lead

NCT06550167Not ApplicableRecruiting

Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances

Role: lead

NCT06432816Not ApplicableRecruiting

Efficacy of Nano-Pso Therapy in Menopause

Role: lead

NCT05142085Not ApplicableUnknown

Efficacy of Nano-PSO in Parkinson's Disease.

Role: lead

All 4 trials loaded